We explored the clinical value of monitoring hTERT cfDNA levels and detected the presence of CTCs, including PD‐L1 characterization, in a homogeneous cohort of patients with metastatic NSCLC receiving first‐line treatment with pembrolizumab as a monotherapy or in combination with chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.